ファイザー、HYMPAVZIのsBLAがFDAに受理 優先審査付与で小児・インヒビター保有血友病へ適応拡大目指す | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究

U.S. FDA Accepts Pfizer’s Supplemental Biologics License Application for Priority Review of HYMPAVZI (marstacimab)

stellanews.life/technology/8...

#Hemophilia #Pfizer #FDA #HYMPAVZI #PriorityReview #ClinicalTrials

#Marstacimab ya está aprobado en China para la prevención de sangrados 🩸
👉 Hemofilia A y B
👉 ≥12 años | ≥35 kg
📎 Más información: dengyuemed.com/product/mars...
📧 info@dengyuemed.com
#HYMPAVZI #Hemofilia #DeficienciaDelFactorVIII #DeficienciaDelFactorIX #DengYueMedicinasEnHongKong

Pfizer says patient dies after receiving hemophilia drug in trial A patient who was being treated with Pfizer’s PFE.N hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said. The individual died on December 14 after suffering a stroke followed by a brain hemorrhage, according to the European Haemophilia Consortium, a patient support group. The patient was enrolled in a study that was […] The post Pfizer says patient dies after receiving hemophilia drug in trial appeared first on Interaksyon.